Infants With Spinal Muscular Atrophy Type I

Spinal Muscular Atrophy Clinical Trial

Official title:

A Pilot Study of the Natural History of Infants With Spinal Muscular Atrophy (SMA) Type 1

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01547871
• Other study ID #: 999912067
• Secondary ID: 12-N-N067
• Status: Terminated
• Start date: February 7, 2012
• Est. completion date: April 14, 2016

Study information

• Verified date: April 14, 2016
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

• Spinal muscular atrophy type 1 (SMA 1) causes severe muscle weakness and problems with eating and breathing. The symptoms begin in infancy, and children affected with SMA 1 often die in early childhood. Researchers want to collect information on how SMA symptoms progress in first two years.

Objectives:

• To study how the symptoms of SMA 1 progress in infants and children.

Eligibility:

• Infants and children with SMA 1 born on or after January 1, 2007.

Design:

• Researchers will review the child s medical records and talk with parents by telephone.

• For children who are under 2 years of age, the researchers will review the child s medical records and speak with you on telephone every 2-4 months. Phone calls with parents will take about 10 minutes and will involve questions about symptoms of SMA 1. Children will be followed until age 2.- Researchers are also interested in looking at medical records of children who are no longer alive or who are more than 2 years of age.

Parents or children do not have to come to the NIH. They will provide consent to view these records, and information over the telephone.

• No treatment or care will be provided as part of this study.

Description:

Objective:

To conduct a pilot, observational, retrospective and prospective, natural history study of infants affected with spinal muscular atrophy type 1 (SMA 1). The goal is to assess the feasibility of the study design in order to plan a larger study aimed at understanding the changing natural history and obtain current data on survival of patients affected with SMA 1. This information is important for designing clinical trials.

Study Population:

Up to 50 children born on or after January 1, 2007 with a clinical diagnosis of SMA 1 and genetic testing consistent with a homozygous mutation of the SMN 1 gene on chromosome 5q13 will be enrolled in the study.

Design:

This is a longitudinal pilot study to demonstrate study design feasibility and test outcome measures to assess the natural history of infants affected with SMA 1. Pertinent clinical and demographic data will be collected. The data collection will be retrospective for deceased infants and children who are alive but over age of 2 years at the time of enrollment. A combination of retrospective and prospective data will be collected for infants who are alive and less than 2 years of age at the time of enrollment. The data will be collected remotely from the National Institutes of Health (NIH) by medical chart reviews and/or telephone questionnaire obtained from the parent of the infant with SMA 1. Infants alive at enrollment will be followed prospectively until age 2 years or death, whichever occurs first.

Outcome Measures:

The primary outcome of this pilot study is to demonstrate the feasibility of the study design and outcome measures in patients with SMA 1.

Secondary outcomes include evaluation for time of events, i.e., time of ventilator support for >=16 hours a day continuously for more than 2 weeks and time of death.

Additional demographic and clinical data pertinent to respiratory and nutritional aspects will be collected to assess possible factors influencing the outcome measures.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: April 14, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 6 Years

Eligibility

• INCLUSION CRITERIA:

1. Diagnosis of SMA 1 in infancy (i.e. less than 2 years of age)

2. Symptoms of motor weakness and hypotonia, as documented by a clinician with onset before age 6 months

3. Inability to sit without support at age 8 months

4. Genetic testing consistent with mutation or deletion of the SMN 1 gene on chromosome 5q

5. Born on or after January 1, 2007

6. At least one parent is able to provide written informed consent

7. Born and living in United States of America

EXCLUSION CRITERIA:<TAB>

1. Anticipated excessive emotional distress to the parents or caregivers from research procedures, based on physician and parent evaluation.

Related Conditions & MeSH terms

• Atrophy
• Muscular Atrophy
• Muscular Atrophy, Spinal
• Spinal Muscular Atrophy

Locations

Country	Name	City	State
United States	National Institute of Neurological Disorders and Stroke (NINDS), 9000 Rockville	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics. 2004 Nov;114(5):e548-53. Epub 2004 Oct 18. — View Citation

Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, De Vivo DC, Kaufmann P. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007 Nov 13;69(20):1931-6. — View Citation

Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005 May;57(5):704-12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome of this pilot study is to demonstrate the feasibility of the study design and test the outcome measures in patients with SMA 1.
Secondary	Secondary outcomes include evaluation for time of events, i.e., time of ventilator support for greater than or equal to 16 hours a day continuously for more than 2 weeks and time of death.